- Home
- SPNT vs MRUS Comparison
SPNT vs MRUS Comparison
Compare SPNT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNT
- MRUS
- Stock Information
- Founded
- SPNT 2011
- MRUS 2003
- Country
- SPNT Bermuda
- MRUS Netherlands
- Employees
- SPNT N/A
- MRUS N/A
- Industry
- SPNT Property-Casualty Insurers
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SPNT Finance
- MRUS Health Care
- Exchange
- SPNT Nasdaq
- MRUS Nasdaq
- Market Cap
- SPNT 2.3B
- MRUS 2.7B
- IPO Year
- SPNT N/A
- MRUS 2016
- Fundamental
- Price
- SPNT $16.70
- MRUS $43.06
- Analyst Decision
- SPNT Hold
- MRUS Strong Buy
- Analyst Count
- SPNT 1
- MRUS 13
- Target Price
- SPNT $17.00
- MRUS $86.85
- AVG Volume (30 Days)
- SPNT 915.9K
- MRUS 872.0K
- Earning Date
- SPNT 04-29-2025
- MRUS 05-07-2025
- Dividend Yield
- SPNT N/A
- MRUS N/A
- EPS Growth
- SPNT N/A
- MRUS N/A
- EPS
- SPNT 1.04
- MRUS N/A
- Revenue
- SPNT $2,656,400,000.00
- MRUS $36,133,000.00
- Revenue This Year
- SPNT N/A
- MRUS $26.81
- Revenue Next Year
- SPNT N/A
- MRUS $23.85
- P/E Ratio
- SPNT $16.07
- MRUS N/A
- Revenue Growth
- SPNT N/A
- MRUS N/A
- 52 Week Low
- SPNT $11.49
- MRUS $33.19
- 52 Week High
- SPNT $17.99
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- SPNT 57.59
- MRUS 51.15
- Support Level
- SPNT $16.22
- MRUS $33.19
- Resistance Level
- SPNT $16.61
- MRUS $43.46
- Average True Range (ATR)
- SPNT 0.77
- MRUS 3.53
- MACD
- SPNT -0.06
- MRUS 0.34
- Stochastic Oscillator
- SPNT 60.06
- MRUS 80.53
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.